Search results for "LIVER DISEASE"

showing 10 items of 913 documents

C4BQ0: a genetic marker of familial HCV-related liver cirrhosis

2004

Source Department of Medicine and Pneumology, V Cervello Hospital, Via Trabucco 180, 90146 Palermo, Italy. lindpas@yahoo.it Abstract BACKGROUND AND METHODS: Host may have a role in the evolution of chronic HCV liver disease. We performed two cross-sectional prospective studies to evaluate the prevalence of cirrhosis in first degree relatives of patients with cirrhosis and the role of two major histocompatibility complex class III alleles BF and C4 versus HCV as risk factors for familial clustering. FINDINGS: Ninety-three (18.6%) of 500 patients with cirrhosis had at least one cirrhotic first degree relative as compared to 13 (2.6%) of 500 controls, (OR 7.38; CI 4.21-12.9). C4BQ0 was signifi…

AdultGenetic MarkersLiver Cirrhosismedicine.medical_specialtyCirrhosisAdolescentFamilial clusteringFamilial clusteringGastroenterologyLiver cirrhosiC4BQ0Liver diseaseInternal medicineHCV diffusionComplement C4bPrevalencemedicineHumansProspective StudiesAlleleFamily historyFirst-degree relativesMHC class III allelesChildProspective cohort studyAllelesAgedAged 80 and overHepatologybusiness.industryGastroenterologyHepatitis C ChronicMiddle Agedmedicine.diseaseCross-Sectional StudiesGenetic markerbusinessC4BQ0; Familial clustering; HCV diffusion; Liver cirrhosis; MHC class III allelesDigestive and Liver Disease
researchProduct

Complications in Immunosuppressive Therapy of Liver Transplant Recipients

2011

BACKGROUND: In liver transplantation (LT), modern immunosuppressive protocol is focused on early corticosteroid (CS) weaning. The aim of the study was to investigate all early transplant-related complications using Clavien grading system, in order to identify a significant relation in two homogenous groups of consecutive liver transplanted patients, only different for steroid avoidance in immunosuppressive regimen. MATERIALS AND METHODS: One group was treated with a tacrolimus-based CS-free immunosuppressive protocol, the other one underwent tacrolimus plus low dose CS therapy. The preoperative continuous variables analyzed were age, gender, model for end-stage liver disease (MELD) score, a…

AdultGraft RejectionMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatecomplicationLiver transplantationGastroenterologyTacrolimusYoung AdultLiver diseasePostoperative ComplicationsAdrenal Cortex HormonesInternal medicinemedicineHumansAgedRetrospective Studiesimmunosuppressionbusiness.industryIncidenceLiver DiseasesIncidence (epidemiology)ImmunosuppressionMiddle Agedmedicine.diseaseTacrolimusLiver TransplantationSurgerySurvival RateRegimenCorticosteroidDrug Therapy CombinationFemaleSurgeryrejectionComplicationbusinessImmunosuppressive AgentsJournal of Surgical Research
researchProduct

Liver transplantation: the Italian experience

2002

Abstract Background. Liver transplantation is the standard treatment for patients with end-stage liver disease no longer responsive to conventional medical treatment Aims . To report the longterm experience of liver transplantation in Italy. Patients and Methods . Data were obtained retrospective by means of a multiple-item form collected from 15 Italian liver transplant centres. The filing centre was centralized. Results . A total of 3323 liver transplants were performed on 3026 patients, with a cumulative proportional survival of 72.4%. Three, 5 and 10 years' patient survival rates were 72.3%, 68.8% and 61.3%, respectively. The most common indication for liver transplantation were hepatit…

AdultGraft RejectionMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisAdolescentmedicine.medical_treatmentLiver transplantationGastroenterologyLiver diseaseRecurrenceInternal medicinePrevalenceMedicineHumansAgedRetrospective StudiesLiver transplantationHepatologybusiness.industryLiver DiseasesPatient SelectionGastroenterologyHepatitis CHepatitis BMiddle Agedmedicine.diseaseTransplantationSurvival RateItalyFemaleHepatitis D virusbusinessLiver disease
researchProduct

Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion

2003

Abstract Ischemic-type biliary lesions (ITBLs) lead to considerable morbidity after orthotopic liver transplantation (OLT). The exact pathogenesis is unknown. We tested the hypothesis that insufficient perfusion of biliary arterial vessels might be responsible for ITBLs. This could be prevented by improved perfusion techniques. Since February 2000, we performed a controlled study using arterial back-table pressure perfusion (AP) to achieve reliable perfusion of the biliary-tract capillary system, which may be impaired by the high viscosity of University of Wisconsin solution. We retrospectively analyzed 190 OLTs performed between September 1997 and July 2002 with regard to ITBLs. One hundre…

AdultGraft Rejectionmedicine.medical_specialtyAdenosineOrthotopic liver transplantationAllopurinolmedicine.medical_treatmentOrgan Preservation SolutionsUrologyLiver transplantationPathogenesisPostoperative ComplicationsRaffinosePressuremedicineHumansInsulinViaspanAlanine aminotransferaseAgedRetrospective StudiesTransplantationHepatologyViscositybusiness.industryLiver DiseasesGraft SurvivalImmunosuppressionMiddle AgedGlutathioneStandard techniqueLiver TransplantationSurgeryPerfusionSurvival RateReperfusion InjurySurgeryBile DuctsbusinessPerfusionImmunosuppressive AgentsLiver Transplantation
researchProduct

AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.

2020

Lysosomal storage diseases (LSDs) are a heterogeneous group of inherited disorders caused by loss-of-function mutations in genes encoding for lysosomal enzymes/proteins. The consequence is a progressive accumulation of substrates in these intracellular organelles, resulting in cellular and tissue damage. The overall incidence is about 1/8000 live births, but is likely underestimated. LSDs are chronic progressive multi-systemic disorders, generally presenting with visceromegaly, and involvement of the central nervous system, eyes, the skeleton, and the respiratory and cardiovascular systems. The age at onset and phenotypic expression are highly variable, according to the specific enzymatic d…

AdultHepatosplenomegalyLysosomal acid lipase deficiencyBioinformaticsOrganomegaly03 medical and health sciencesLiver disease0302 clinical medicinemedicineCholesteryl ester storage disease Enzyme replacement therapy Gaucher disease Lysosomal acid lipase Niemann–Pick disease deficiency Substrate reduction therapyHumansSubstrate reduction therapyEnzyme Replacement TherapySocieties MedicalNiemann-Pick DiseasesAcid sphingomyelinase deficiencyGaucher DiseaseHepatologybusiness.industryGastroenterologyWolman DiseaseEnzyme replacement therapymedicine.diseaseLysosomal Storage DiseasesSphingomyelin PhosphodiesteraseItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologymedicine.symptombusinessNiemann–Pick diseaseLysosomesVisceromegalyDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Update on autoimmune hepatitis

2009

Autoimmune hepatitis (AIH) is a necroinflammatory liver disease of unknown etiology that occurs in children and adults of all ages. Characteristics are its autoimmune features, hyperglobulinemia (IgG), and the presence of circulating autoantibodies, as well as a response to immunosuppressant drugs. Current treatment consists of prednisone and azathioprine and in most patients this disease has become very treatable. Over the past 2 years, a couple of new insights into the genetic aspects, clinical course and treatment of AIH have been reported, which will be the focus of this review. In particular, we concentrate on genome-wide microsatellite analysis, a novel mouse model of AIH, the evaluat…

AdultHyperglobulinemiaAzathioprineAutoimmune hepatitisDiseaseAntibodiesLiver diseaseLife ExpectancyAdrenal Cortex Hormonesimmune system diseasesPrednisonemedicineHumansSurvivorsChildHepatitisGenome Humanbusiness.industryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIThyroiditis AutoimmuneGastroenterologyAutoantibodyDNAGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneEditorialImmunoglobulin GImmunologybusinessImmunosuppressive AgentsMicrosatellite Repeatsmedicine.drugWorld Journal of Gastroenterology
researchProduct

Negative biopsy of focal hepatic lesions: Decision tree model for patient management

2019

OBJECTIVE. The purpose of this study was to investigate patient- and procedure-related variables affecting the false-negative rate of ultrasound (US)-guided liver biopsy and to develop a standardized patient-tailored predictive model for the management of negative biopsy results. MATERIALS AND METHODS. We retrospectively included 389 patients (mean age ± SD, 62 ± 12 years old) who had undergone US-guided liver biopsy of 405 liver lesions between January 1, 2013, and June 30, 2015. We collected multiple patient- and procedure-related variables. By comparing pathology reports of biopsy and the reference standard (further histology or imaging follow-up), we were able to categorize the biopsy r…

AdultImage-Guided BiopsyMalemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingFalse Negative Result030218 nuclear medicine & medical imaging03 medical and health sciencesCore biopsyFalse-negative result0302 clinical medicineBiopsymedicineHumansFalse Negative ReactionsUltrasonography InterventionalAgedRetrospective StudiesAged 80 and overFine-needle aspirationmedicine.diagnostic_testUS-guided liver biopsybusiness.industryLiver DiseasesDecision TreesUltrasoundnutritional and metabolic diseasesGeneral MedicineMiddle AgedPatient managementDiagnostic errorFine-needle aspiration030220 oncology & carcinogenesisLiver biopsyFemaleRadiologybusinessCore biopsyDecision tree model
researchProduct

"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".

2022

Objectives Non-alcoholic fatty liver disease (NAFLD) is strongly associated with cardiovascular disease in the general population. We aimed to assess the impact of NAFLD and liver fibrosis on intermediate-high cardiovascular risk in people living with HIV. Methods We included people living with HIV from three cohorts. NAFLD and significant liver fibrosis were defined using transient elastography: controlled attenuation parameter >= 288 dB/m and liver stiffness measurement >= 7.1 kPa, respectively. Cardiovascular risk was assessed with the atherosclerotic cardiovascular disease (ASCVD) risk estimator in patients aged between 40 and 75 years and categorised as low if <5%, borderline …

AdultLiver CirrhosisLiver CirrhosiHIV InfectionsBMIElasticity Imaging TechniqueNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseHumansHIV InfectionPharmacology (medical)Prospective StudiesNon-alcoholic Fatty Liver Disease.AgedASCVD score; BMI; controlled attenuation parameter; HIV mono-infection; transient elastographyASCVD scoreRisk FactorHealth PolicyHIV mono-infectionHeart Disease Risk FactorMiddle Agedtransient elastographycontrolled attenuation parameterProspective StudieInfectious DiseasesLiverCardiovascular DiseasesHeart Disease Risk FactorsElasticity Imaging TechniquesHumanHIV medicineREFERENCES
researchProduct

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

2018

AbstractLiver biopsy is currently the only reliable method to establish nonalcoholic fatty liver disease (NAFLD) severity. However, this technique is invasive and occasionally associated with severe complications. Thus, non-invasive diagnostic markers for NAFLD are needed. Former studies have postulated 18 different serum microRNA biomarkers with altered levels in NAFLD patients. In the present study, we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort. Moreover, miR-192, -27b, -22, -197 and -30c appeared specific for NAFLD, when compared wi…

AdultLiver CirrhosisMale0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineSeverity of Illness Indexdigestive systemArticleCohort Studies03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicinemicroRNANonalcoholic fatty liver diseasemedicineHumansCirculating MicroRNAlcsh:ScienceSerum micrornaAgedLiver injuryMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RLiquid BiopsyMiddle AgedPrognosismedicine.diseasedigestive system diseasesCirculating MicroRNA030104 developmental biologyLiverLiver biopsyCohortDisease ProgressionFemalelcsh:QbusinessBiomarkers
researchProduct

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study

2018

Background & Aims The non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. Methods We analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fi…

AdultLiver CirrhosisMale0301 basic medicinemedicine.medical_specialtysteatohepatitisSeverity of Illness IndexGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineHumansMedicineIn patientProspective StudiesKeratin-18Hepatologymedicine.diagnostic_testbusiness.industryFatty liverExternal validationReproducibility of ResultsMiddle Agedmedicine.disease3. Good health030104 developmental biologyItalyLiverROC Curvenon-invasive markerLiver biopsyCohortElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatohepatitisfibrosibusinessAlgorithmsBiomarkersLiver International
researchProduct